METTL14 and non-small cell lung carcinoma: Currently, several biotechnology companies have announced that they have developed small-molecule inhibitors of the METLL3-METTL14 complex targeting different types of cancer, such as AML and non-small cell lung cancer (NSCLC), and they are preparing to conduct clinical phase-I trials in 2021–2022.